Skip to main content

Welcome Dr. Kelsey, Johnson!

October 15, 2024

Dr. Johnson is a geriatric psychiatrist who specializes in treating mental health concerns and neurocognitive disorders in older adults. She works in inpatient , outpatient , and long term care settings. Her areas of interest include the behavioral and psychological symptoms of dementia , caregiver burnout , and resident education.

Facilitated Peer Group Mentoring for Underrepresented Biomedical Researchers: Facilitators’ Experiences and Implications for Dissemination of a Curriculum

October 1, 2024

Peer group mentoring facilitated by senior faculty represents an effective approach. We explored motivations, benefits, and challenges for facilitators enrolled to deploy an intervention in the context of a randomized controlled trial that tested two peer group mentoring strategies for underrepresented early career researchers.

Early cognitive development and psychopathology in children at familial high risk for schizophrenia

October 1, 2024

We studied cognitive development and psychopathology in children 4 and 6 years old who where at familial risk for developing schizophrenia and found delayed cognitive development and high rates of symptoms such as anxiety and attention problems, earlier than has previously been described. This indicates that risk for schizophrenia is expressed early in childhood, and … Read more

Research with women sexual assault survivors presenting for emergency care is safe: Results from a multi-site, prospective observational cohort study

October 1, 2024

A large cohort of 706 women sexual assault survivors presenting to emergency care were recruited nationwide and followed over one year post-assault. Our findings suggested that the vast majority of women rated their research experience as positive (95-97%), denied drawbacks (84-89%), and reported participating was worth it (93-95%), and these positive experiences were stable and … Read more

Analysis of Depression and Anxiety Scores Following Initiation of Elexacaftor/Tezacaftor/Ivacaftor in Adults With Cystic Fibrosis.

October 1, 2024

This work examines whether there are changes in the self-report of anxiety and depression symptoms in adults with cystic fibrosis (CF) who started taking elexacaftor/tezacaftor/ivacaftor (E/T/I), a new medication that shows great promise in the treatment of CF. The study found that there were no changes in these symptoms in the overall study population, but … Read more